<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization - Health AI Hub</title>
    <meta name="description" content="FRAGMENTA introduces an end-to-end generative AI framework for drug lead optimization, addressing challenges of limited data and slow model tuning by jointly op">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20510v2" target="_blank">2511.20510v2</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yuto Suzuki, Paul Awolade, Daniel V. LaBarbera, Farnoush Banaei-Kashani
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20510v2" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20510v2" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">FRAGMENTA introduces an end-to-end generative AI framework for drug lead optimization, addressing challenges of limited data and slow model tuning by jointly optimizing molecular fragmentation and generation using dynamic Q-learning. It integrates an agentic AI system that refines objectives through conversational expert feedback, aiming to automate the tuning process. In cancer drug discovery, the Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines, and the autonomous Agent-Agent system outperformed traditional Human-Human tuning.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This framework significantly accelerates and enhances the efficiency of drug lead optimization, particularly crucial for rare diseases or specific targets with limited data, by generating more effective candidate molecules and streamlining the iterative design and tuning process, potentially speeding up drug development pipelines.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>FRAGMENTA is an end-to-end AI framework designed to accelerate drug lead optimization. It comprises a novel generative AI model for creating drug molecules by reframing fragmentation, combined with an agentic AI system that automates the tuning process by learning from conversational feedback from domain experts (e.g., medicinal chemists). This system aims to improve the efficiency and success rate of identifying high-scoring drug candidates, demonstrated in the context of cancer drug discovery, thereby directly impacting the development of new therapies and healthcare.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical challenges in drug discovery: scarcity of class-specific datasets (often <100 examples) and the inefficiency of traditional, indirect model tuning processes.</li>
                    
                    <li>Introduces a novel generative model that reframes molecular fragmentation as a 'vocabulary selection' problem, moving beyond heuristic approaches.</li>
                    
                    <li>Employs dynamic Q-learning to jointly optimize both the fragmentation process and the subsequent molecule generation, enhancing diversity and relevance.</li>
                    
                    <li>Incorporates an agentic AI system designed to refine generative objectives through direct conversational feedback from domain experts (e.g., medicinal chemists).</li>
                    
                    <li>The agentic system aims to remove the AI engineer from the iterative tuning loop and progressively learn domain knowledge for eventual full automation of the tuning process.</li>
                    
                    <li>In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly double the number of high-scoring molecules compared to baseline methods.</li>
                    
                    <li>The fully autonomous Agent-Agent system demonstrated superior performance over traditional Human-Human expert tuning, affirming the efficacy of agentic tuning in capturing and operationalizing expert intent.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FRAGMENTA employs a two-part framework: a novel generative model utilizing dynamic Q-learning for the joint optimization of molecular fragmentation (redefined as vocabulary selection) and molecule generation, coupled with an agentic AI system that refines model objectives through conversational feedback from human domain experts, thereby automating and learning the tuning process.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>FRAGMENTA's Human-Agent configuration demonstrated a near doubling in the identification of high-scoring molecules compared to baseline methods in cancer drug discovery experiments. Crucially, the fully autonomous Agent-Agent system surpassed traditional Human-Human expert tuning, validating its ability to effectively capture and operationalize expert intent for objective refinement.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This technology has the potential to dramatically reduce the time and cost associated with the early stages of drug discovery, by rapidly identifying and optimizing highly potent and relevant drug candidates. This could lead to faster development of new therapies, particularly for challenging diseases like cancer, by providing medicinal chemists with superior leads more efficiently and automating expert-guided refinement cycles.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the FRAGMENTA framework itself. Instead, it highlights that FRAGMENTA aims to overcome critical limitations of existing methods, such as the severe scarcity of class-specific training data, the diversity constraints imposed by existing heuristic molecular fragmentation techniques, and the inefficiency and slowness of traditional, human-dependent model tuning processes.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract explicitly points to the agentic AI system's goal to "progressively learn domain knowledge to eventually automate tuning," indicating a future research direction focused on achieving full autonomy in the drug lead optimization pipeline through continuous learning of expert intent.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Drug Design</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Drug Discovery</span>
                    
                    <span class="tag tag-keyword">Lead Optimization</span>
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Molecular Fragmentation</span>
                    
                    <span class="tag tag-keyword">Q-learning</span>
                    
                    <span class="tag tag-keyword">Agentic AI</span>
                    
                    <span class="tag tag-keyword">Cancer Drugs</span>
                    
                    <span class="tag tag-keyword">Automated Tuning</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Molecule generation using generative AI is vital for drug discovery, yet class-specific datasets often contain fewer than 100 training examples. While fragment-based models handle limited data better than atom-based approaches, existing heuristic fragmentation limits diversity and misses key fragments. Additionally, model tuning typically requires slow, indirect collaboration between medicinal chemists and AI engineers. We introduce FRAGMENTA, an end-to-end framework for drug lead optimization comprising: 1) a novel generative model that reframes fragmentation as a "vocabulary selection" problem, using dynamic Q-learning to jointly optimize fragmentation and generation; and 2) an agentic AI system that refines objectives via conversational feedback from domain experts. This system removes the AI engineer from the loop and progressively learns domain knowledge to eventually automate tuning. In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in capturing expert intent.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>